Street Calls of the Week
On Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on Sarepta Therapeutics stock, maintaining a price target of $163.00 per share. Currently trading at $100.60, near its 52-week low of $100.14, the stock has attracted varied analyst targets ranging from $75 to $215. The firm’s analysts updated their financial model for the company for the year ending December 31, 2024, adjusting revenue and operating expense estimates to align with the guidance provided by Sarepta Therapeutics.
The adjustments made by Cantor Fitzgerald’s analysts reflect the latest information from Sarepta Therapeutics regarding its financial outlook. The company has demonstrated strong performance with revenue growth of 53% over the last twelve months, reaching $1.9 billion. The company’s guidance has been taken into account, leading to revisions in the expected revenue and operating expenses for the period in question. InvestingPro analysis reveals 13 additional key insights about Sarepta’s financial position and growth prospects.
Despite these updates to the financial model, Cantor Fitzgerald has not altered its 12-month price target for Sarepta Therapeutics, which remains at $163 per share. The firm’s continued confidence in the stock is evident from the maintained Overweight rating and price target, suggesting a positive outlook on the company’s performance. InvestingPro data shows the company maintains a healthy financial position with a current ratio of 4.2 and has received an overall "GOOD" Financial Health score.
Sarepta Therapeutics, listed on (NASDAQ:SRPT), is a biotechnology company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The company’s commitment to innovation and development in this field is a key aspect of its business strategy.
Investors and market watchers may find Cantor Fitzgerald’s steady price target and rating of interest as they evaluate Sarepta Therapeutics’ stock performance and future prospects. The updated financial model and the firm’s reaffirmed stance provide a current snapshot of the company’s valuation according to Cantor Fitzgerald’s analysis.
In other recent news, Sarepta Therapeutics has reported significant financial achievements for the fourth quarter of 2024, with earnings per share (EPS) of $1.9, surpassing analysts’ expectations of $1.54. The company’s revenue for the quarter reached $658.4 million, exceeding the anticipated $589.45 million, driven by strong sales of Alevitus. Despite this strong performance, the company’s stock price experienced a decline in aftermarket trading. Sarepta maintains its guidance for 2025, projecting net product revenue between $2.9 billion and $3.1 billion, indicating a potential 70% increase. Analyst firms RBC Capital and Mizuho (NYSE:MFG) Securities both adjusted their price targets for Sarepta, with RBC lowering it to $161 and Mizuho to $190, while both maintained an Outperform rating. RBC Capital noted the underappreciation of Sarepta’s pipeline, particularly in limb-girdle muscular dystrophy type 2E treatments. Mizuho highlighted the growth potential for Elevidys, a treatment for Duchenne muscular dystrophy, emphasizing the opportunity for increased adoption. These developments underscore the company’s ongoing strategic focus on expanding its gene therapy pipeline and market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.